NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
25 trialsNCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT06096779 2026-03-06
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05733598 2025-12-15
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune Inc.
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07239245 2025-11-25
ATTACH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT06789757 2025-10-07
(HCC)
Inova Health Care Services
Phase 2 Recruiting
NCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05168163 2025-09-16
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT05690048 2025-08-06
FLORA
University Hospital Heidelberg
Phase 2 Recruiting
NCT06339424 2025-05-14
PhotonAB
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT05750030 2025-05-06
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
Phase 2 Completed
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT05625893 2024-11-29
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
Phase 2 Recruiting
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT05396937 2022-05-31
Efficacy and Safety of T+A+RAD in HCC
Fudan University
Phase 2 Unknown